These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27999068)

  • 1. Linezolid: a promising option in the treatment of Gram-positives.
    Zahedi Bialvaei A; Rahbar M; Yousefi M; Asgharzadeh M; Samadi Kafil H
    J Antimicrob Chemother; 2017 Feb; 72(2):354-364. PubMed ID: 27999068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid.
    Narang M; Gomber S
    Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxazolidinone antibiotics.
    Diekema DJ; Jones RN
    Lancet; 2001 Dec; 358(9297):1975-82. PubMed ID: 11747939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
    Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid resistance in a clinical isolate of Staphylococcus aureus.
    Tsiodras S; Gold HS; Sakoulas G; Eliopoulos GM; Wennersten C; Venkataraman L; Moellering RC; Ferraro MJ
    Lancet; 2001 Jul; 358(9277):207-8. PubMed ID: 11476839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing Linezolid-resistant Enterococcus in a Children's Hospital.
    Bagga B; Buckingham S; Arnold S; Nesbitt A; Guimera D; Lee K
    Pediatr Infect Dis J; 2018 Mar; 37(3):242-244. PubMed ID: 29189675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid: a review of its properties, function, and use in critical care.
    Hashemian SMR; Farhadi T; Ganjparvar M
    Drug Des Devel Ther; 2018; 12():1759-1767. PubMed ID: 29950810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antibacterial agents for the treatment of serious Gram-positive infections.
    Abbanat D; Macielag M; Bush K
    Expert Opin Investig Drugs; 2003 Mar; 12(3):379-99. PubMed ID: 12605562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
    Krueger WA; Unertl KE
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by Gram-positive pathogens.
    Chen YS; Lee SC; Kim WJ
    J Formos Med Assoc; 2004 May; 103(5):349-54. PubMed ID: 15216400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update of antimicrobial resistance in Gram-positive microorganisms].
    Cercenado E
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():10-5. PubMed ID: 21477699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
    Jankowski A; Stefanik W
    Wiad Lek; 2006; 59(9-10):727-31. PubMed ID: 17338140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.